TrialJournal of the American Academy of Dermatology2022

Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial.

Haley B Naik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.